A phase i study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

British Journal of Cancer

Volumn 106, Issue 10, 2012, Pages 1598-1604

  Boss, D S ^a   Glen, H ^b   Beijnen, J H ^c,d   Keesen, M ^a   Morrison, R ^b   Tait, B ^b   Copalu, W ^e   Mazur, A ^e   Wanders, J ^e   O'Brien, J P ^f   Schellens, J H M ^a,d   Evans, T R J ^b,g  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e EISAI CO LTD   (Japan)

^f EISAI INC   (United States)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Dose escalation; E7080; pharmacokinetics; phase I; receptor tyrosine kinase inhibitor; solid tumours

Indexed keywords

LENVATINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPHONIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETHARGY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PRIORITY JOURNAL; PROTEINURIA; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINOLINES;

EID: 84860780755     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.154     Document Type: Article

References (37)

1. Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P (2009) Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther 9: 1583-1598
2. Curtin JA, Busam K, Pinkel D, Bastian BC (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346 (Pubitemid 46630793)
3. Dvorak HF (2005) Angiogenesis: update 2005. J Thromb Haemost 3: 1835-1842 (Pubitemid 41716570)
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134 (Pubitemid 46089673)
5. Eskens FA, Verweij J (2006) The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 42: 3127-3139 (Pubitemid 44869016)
6. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25-35 (Pubitemid 46630490)
7. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676 (Pubitemid 36749215)
8. Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175: 409-416
9. Glen H, Boss D, Evans TRJ, Roelvink M, Saro JM, Bezodis P, Copalu W, Das A, Crosswell G, Schellens JH (2007) A phase I dose finding study of E7080 in patients (pts) with advanced malignancies. J Clin Oncol 25(18S): 617s (abstract 14073)
10. Glen H, Boss DR, Morrison R, Roelvink M, Wanders A, Mazur A, Gupta A, Das A, Evans TRJ, Schellens JH (2008) A phase I study of E7080 in patients (pts) with advanced malignancies. J Clin Oncol 26(15S): 159s (abstract 3526)
11. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29: 2904-2909
12. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352: 895-904 (Pubitemid 40300298)
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 (Pubitemid 38702844)
14. Ivy SP, Wick JY, Kaufman BM (2009) An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6: 569-579
15. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795 (Pubitemid 46912024)
16. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132
17. Keizer RJ, Gupta A, Mac Gillavry MR, Jansen M, Wanders J, Beijnen JH, Schellens JH, Karlsson MO, Huitema AD (2010) A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn 37: 347-363
18. Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a classeffect of antiangiogenic therapies. Anticancer Drugs 20: 81-82
19. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008a) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465
20. Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008b) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664-671 (Pubitemid 350308963)
21. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM (2010) Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41: 375-384
22. Minor DR, Kashani-Sabet M, Garrido M, O'Day SJ, Hamid O, Bastian BC (2012) Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res 18: 1457-1463
23. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124 (Pubitemid 46089672)
24. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu MY, Dejesus E, McBrian M, Gupta AR, Eck SL, Herlyn M (1999) Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 18: 6469-6476
25. Ott PA, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J, Yee H, Buckley M, Christos PJ, Wright JJ, Polsky D, Osman I, Liebes L, Pavlick AC (2010) A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 5: e15588
26. Ozen M, Medrano EE, Ittmann M (2004) Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. Melanoma Res 14: 13-21 (Pubitemid 38392409)
27. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as firstline therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27: 1227-1234
28. Rixe O, Dutcher K, Motzer RJ, Wilding G, Stadler WM, Garrett M, Pithavala Y, Kim S, Tarazi J, Rini BI (2009) Diastolic blood pressure (DBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 2715(Suppl): Abstract 5045
29. Roodhart JM, Langenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3: 132-143
30. Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580: 2879-2887 (Pubitemid 43729175)
31. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF (1990) Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50: 1774-1778 (Pubitemid 20098819)
32. Sherman SI, Jarzab B, Cabanillas ME, Licitra LF, Pacini F, Martins R, Robinson B, Ball D, McCaffrey J, Shah MH, Bodenner D, Allison R, Newbold K, Elisei R, O'Brien JP, Schlumberger M (2011) A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2915(Suppl): Abstract 5503
33. Strumberg D, Awada A, Hirte H, Clark JW, Seeber S, Piccart P, Hofstra E, Voliotis D, Christensen O, Brueckner A, Schwartz B (2006) Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 42: 548-556 (Pubitemid 43227936)
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
35. Verheul HM, Voest EE, Schlingemann RO (2004) Are tumours angiogenesis-dependent? J Pathol 202: 5-13 (Pubitemid 38072840)
36. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T (2011) Phase I doseescalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 17: 2528-2537
37. Yayon A, Ma YS, Safran M, Klagsbrun M, Halaban R (1997) Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinasedeficient FGF receptor 1: evidence for the involvement of Src-family kinases. Oncogene 14: 2999-3009 (Pubitemid 27336315)